For instance, in a clinical phase 1b-2 trial, pembrolizumab (PD-1 antibodies) combined with trastuzumab in women with trastuzumab-resistant, metastatic HER2+ BC has been shown to be safe and effective. Here, ERBB2 is linked to breast cancer.